New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
08:02 EDTSLPSimulations Plus signs five-year reseaerch collaboration agreement with FDA
Simulations Plus has signed a five-year research collaboration agreement with the U.S. Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations. The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches. Under the agreement, Simulations Plus will provide licenses for the Company’s GastroPlus simulation software to model in vivo data representative of challenging absorption characteristics to the FDA's Office of Testing and Research located in the Center for Drug Evaluation and Research Office of Pharmaceutical Science. During the first year, the Company will provide training to FDA investigators regarding the underlying mathematical models. During the course of the collaboration, ideas and recommendations will be exchanged between the FDA and the Company that aim to improve MAM. The collaborators plan to make results from this research available to the public.
News For SLP From The Last 14 Days
Check below for free stories on SLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
07:36 EDTSLPSimulations Plus to host conference call
Subscribe for More Information
July 24, 2014
05:36 EDTSLPSimulations Plus to acquire Cognigen for $7M
Simulations Plus announced that it has entered into an Agreement and Plan of Merger with Cognigen Corporation of Buffalo, New York. Pursuant to the Agreement, upon closing, Cognigen will become a wholly-owned subsidiary of Simulations Plus and will continue to operate under the Cognigen name. This will result in the total number of Simulations Plus employees increasing from 30-65, and is expected to add approximately $5M to the revenues of the combined company in the coming fiscal year. Under the terms of the Agreement, Simulations Plus will pay the shareholders of Cognigen total consideration of $7M, comprised of $2.8M of cash and $4.2M worth of newly-issued, unregistered shares of common stock of Simulations Plus. The Agreement provides that $1.8M of the total consideration will be held back for two years to satisfy any indemnifiable claims that may arise pursuant to the terms of the Agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use